We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current SFOSF market cap is 935.54M. The company's latest EPS is CNY 4.3234 and P/E is 0.39.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Revenue | 28.33B | 30.09B | 38.78B | 43.72B | 41.13B |
| Operating Income | 16.78B | 16.66B | 18.55B | 20.55B | 19.53B |
| Net Income | 3.32B | 3.66B | 4.73B | 3.73B | 2.39B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Total Assets | 76.12B | 83.69B | 93.31B | 107.16B | 113.47B |
| Total Liabilities | 36.92B | 37.7B | 44.93B | 53.05B | 56.85B |
| Total Equity | 39.2B | 45.98B | 48.38B | 54.11B | 56.62B |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CNY (元) | CNY (元) | CNY (元) | CNY (元) | CNY (元) | |
| Operating | 3.22B | 2.58B | 3.94B | 4.22B | 3.41B |
| Investing | -171.96M | -4.71B | -3.86B | -4.06B | -3.82B |
| Financing | -1.94B | 1.47B | -819.41M | 4.43B | -1.34B |
| Market Cap | 935.54M |
| Price to Earnings Ratio | 0.39 |
| Price to Sales Ratio | 0.02 |
| Price to Cash Ratio | 0.1 |
| Price to Book Ratio | 0.02 |
| Dividend Yield | - |
| Shares Outstanding | 551.94M |
| Average Volume (1 week) | 1.13k |
| Average Volume (1 Month) | 26.4k |
| 52 Week Change | -38.20% |
| 52 Week High | 2.8685 |
| 52 Week Low | 1.515 |
| Spread (Intraday) | 0.87 (44.62%) |
| Company Name | Shanghai Fosun Pharmaceuticals Group Company Ltd (PK) |
| Address |
building a, no. 1289 shanghai 200233 |
| Website | https://www.fosunpharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
